Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROSUZET-IVUS: Rosuvastatin + Ezetimibe vs High-dose Rosuvastatin in CAD
NCT03169985Phase 4Active, not recruiting
- Sponsor
- Samsung Medical Center
- Start
- Jul 2017
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of ezetimibe in coronary artery disease (CAD), sponsored by Samsung Medical Center. Started Jul 2017; status: active, not recruiting.
02
Drugs
ezetimibe
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT03169985.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03169985.